Search

Now showing items 1-5 of 5

Duration of immune protection of SARS-CoV-2 natural infection against reinfection.

Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

Fernandes, Queenie; Inchakalody, Varghese Philipose; Merhi, Maysaloun; Mestiri, Sarra; Taib, Nassiba; ... more authors ... less authors ( Taylor and Francis , 2022 , Article)

The emergence of novel and evolving variants of SARS-CoV-2 has fostered the need for change in the form of newer and more adaptive diagnostic methods for the detection of SARS-CoV-2 infections. On the other hand, developing ...

Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron

Vogt, Anne-Cathrine; Augusto, Gilles; Martina, Byron; Chang, Xinyue; Nasrallah, Gheyath; ... more authors ... less authors ( MDPI , 2022 , Article)

In this report, we mechanistically reveal how the Variant of Concern (VOC) SARS-CoV-2 Omicron (B.1.1.529) escapes neutralizing antibody responses, by physio-chemical characterization of this variant in comparison to the ...

Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections.

Qassim, Suelen H; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. This may reflect higher viral load and/or longer duration of ...

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Ahmed, Zaqout; Almaslamani, Muna A.; Chemaitelly, Hiam; Hashim, Samar A.; Ittaman, Ajithkumar; ... more authors ... less authors ( Elsevier , 2022 , Article)

ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe ...